In AML cells, the FTO’s enzymatic activity is inhibited, carrying the IDH (isocitrate dehydrogenase) mutation, which correlates with significantly increased m6A levels (Li et al., 2017b). The gene discussed is IDH3A; the disease is acute myeloid leukemia.